KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $395.7 million.

  • Sarepta Therapeutics' Receivables - Net fell 893.48% to $395.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $395.7 million, marking a year-over-year decrease of 893.48%. This contributed to the annual value of $602.0 million for FY2024, which is 5037.41% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Receivables - Net stood at $395.7 million, which was down 893.48% from $527.3 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Receivables - Net high stood at $659.4 million for Q1 2025, and its period low was $118.2 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Net was $236.8 million (2023), whereas its average is $309.7 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Receivables - Net soared by 8652.13% in 2023 and then crashed by 893.48% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Receivables - Net (Quarter) stood at $153.0 million in 2021, then soared by 40.28% to $214.6 million in 2022, then surged by 86.52% to $400.3 million in 2023, then soared by 50.37% to $602.0 million in 2024, then tumbled by 34.27% to $395.7 million in 2025.
  • Its Receivables - Net stands at $395.7 million for Q3 2025, versus $527.3 million for Q2 2025 and $659.4 million for Q1 2025.